Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GPR52 | Q9Y2T5 | 3/20 | 0.55 |
| ▸ | AURKA | O14965 | 9/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491242 | 0.83 | HDAC3 (0.55) | PHGDHMAPK1ROCK1KDM4EMAPT | |
| SCHEMBL3493497 | 0.83 | GPR52 (0.57) | GPR52AURKAKDM4EMAPTALDH1A1 | |
| SCHEMBL3492442 | 0.81 | ROCK1 (0.57) | MAPK1ROCK1MAPT | |
| SCHEMBL3492157 | 0.80 | KDM5A (0.55) | PHGDHGPR52AURKAKDM4E | |
| SCHEMBL24349565 | 0.79 | GPR52 (0.66) | GPR52AURKAROCK1 | |
| SCHEMBL4238979 | 0.79 | AURKA (0.67) | PHGDHAURKAKDM4EMAPTTHRB | |
| SCHEMBL21090663 | 0.78 | MAPT (0.49) | PHGDHMAPK1L3MBTL1AURKAROCK1 | |
| SCHEMBL581753 | 0.78 | KDM4E (0.55) | PHGDHAURKAKDM4EALDH1A1 | |
| SCHEMBL30772297 | 0.78 | KDM4E (0.55) | PHGDHAURKAKDM4EALDH1A1 | |
| SCHEMBL18286152 | 0.78 | MAPT (0.59) | MAPK1L3MBTL1AURKAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | PHGDH 684/4885MAPK1 251/4885L3MBTL1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.